Both are still in trials but 10 months with chemotherapy versus 2.4 months could bring the drug to the front view of the public, as has been done in the past with activists groups pushing for approval of other drugs. Both are different with treatment plans and the drugs would be limited to the...
Posted to
The Medical Quack .... by Barbara Duck
on 12-04-2008
Filed under: Medically Related, Pharma/FDA News, healthcare, Pharma, Cancer, clinical trials, Prostate Cancer, PSA, R and D, antigen, testosterone
According to the article, the cost is more and you may not feel the customary “puff” as much with the new devices. The new devices tend to clog easier. The reason for the change, the ozone and chlorofluorocarbon that damage, so even the asthma inhalers are going green, not literally I think...
This is the second approval this week for a generic version of Wellbutrin, earlier this week Watson Pharmaceuticals announced it’s new version. BD The Food and Drug Administration approved a generic copy of an antidepressant made by Impax Laboratories Inc. Regulators gave the drug — a copy of GlaxoSmithKline...
The entire focus is to see whether or not patent laws have been violated and if less expensive generics were in any way stalled from getting to the market place. It all boils down to intellectual-property rights and patient disputes. Interesting that Teva is settling lawsuits and will be...
Posted to
The Medical Quack .... by Barbara Duck
on 11-26-2008
Filed under: Medically Related, Pharma/FDA News, Pharma, Generic Drugs, Intellectual property, Lawsuits, Teva, Europe, anti trust
Some issues are a result of still being paper driven as timely reports and real time information are not available, but they are not the only government agency in this scenario, only one of the most critical though. Also, some members of Congress don’t use computers either and felt uncomfortable...
Posted to
The Medical Quack .... by Barbara Duck
on 11-26-2008
Filed under: Medically Related, Technology, Pharma/FDA News, personalized medicine, healthcare, Medical Records, Pharma, FDA, Congress, integration, CMS, Leavitt
Nothing new here in what has been posted, but this time the predictions are coming from within Ernst and Young from India. BD The Indian clinical trials market is predicted to continue its growth despite the current financial climate, according to a partner at Ernst & Young India’s Healthsciences...
Posted to
The Medical Quack .... by Barbara Duck
on 11-25-2008
Filed under: Medically Related, Pharma/FDA News, healthcare, Pharma, clinical trials, R and D, India, Economics, Outsourcing, Employment, Clinic
The post is a summary of how things look today and under related reading I have included some past posts that may offer a few more details on how the shift it taking place today. Things are also happening and humming as well in China and you can search and find some recent relative posts here as...
Posted to
The Medical Quack .... by Barbara Duck
on 11-20-2008
Filed under: Pharma/FDA News, My Commentaries, healthcare, Pharma, clinical trials, R and D, India, Economics, Mayo Clinic, Outsourcing, Employment, China pharma